HomeTagsCymaBay Therapeutics

CymaBay Therapeutics

Healthcare

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

News Desk - February 13, 2024

CymaBay Therapeutics, Inc., a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced that the U.S. Food and...

Biotechnology

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

News Desk - February 13, 2024

Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or...